Pregabalin Viatris Pharma is a medicine used to treat adults with the following conditions: * neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury; * epilepsy, where it is used as an ‘add\-on’ to other epilepsy treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain); * generalised anxiety disorder (long\-term anxiety or nervousness about everyday matters). This medicine is the same as Lyrica, which is already authorised in the European Union (EU). The company that makes Lyrica has agreed that its scientific data can be used for Pregabalin Viatris Pharma (‘informed consent’).
Therapeutic Indication
Neuropathic pain Pregabalin Viatris Pharma is indicated for the treatment of peripheral and central neuropathic pain in adults. Epilepsy Pregabalin Viatris Pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised Anxiety Disorder Pregabalin Viatris Pharma is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Therapeutic Area (MeSH)
ATC Code
N02BF02
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| pregabalin | N/A | pregabalin |
EMA Name
Pregabalin Viatris Pharma (previously Pregabalin Pfizer)
Medicine Name
Pregabalin Viatris Pharma (previously Pregabalin Pfizer)
Aliases
N/ANo risk management plan link.